Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 395

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 395
---
, including Eric Konofal, Eric -JeanDesbois, Bruno Figadere and NLS’s Chief Executive Officer, Alexander Zwyer, or the Pegasus Founders, entered into a license agreement with AP -HP, or the AP -HPLicense Agreement, to obtain a worldwide, sub -licensablelicense, covering four different compounds, which included the use of mazindol for the treatment of ADHD, or the Licensed Compounds. As part of the AP -HPLicense Agreement, Pegasus was given an option to purchase the Licensed Compounds. In February 2016, after the AP -HPLicense Agreement was assigned and transferred to NLS -1, pursuant to an Assignment and Transfer Agreement, or the ATA, NLS -1purchased the Licensed Compounds from AP -HPfor an aggregate consideration of approximately 2.65 million euros, including reimbursement of certain expenses. On April 1, 2017 and September 20, 2019, the parties entered into subsequent amendments of the ATA, or the First Amendment to the ATA and the Second Amendment to the ATA, respectively. Under the Second Amendment to the ATA, NLS agreed to pay Pegasus a royalty of 1.8% of annual net sales (including sublicensee sales) realized upon the commercialization of products developed on the basis of the Licensed Compounds during the terms of their respective patents; provided, however, that under certain circumstances, the rate of the royalty payment will decrease. For instance, if a competing generic product using mazindol for the treatment of ADHD were to become available during the term of the patents covering the Licensed Compounds, there would be no royalties paid to Pegasus. Exclusive License Agreement with Eurofarma In February 2019, NLS entered into a License Agreement with Eurofarma Laboratorios S.A., or Eurofarma and the EF License Agreement, which provided Eurofarma with an exclusive, fee -bearing, non -transferrable(i) distribution right to distribute Nolazol in Latin America and an (ii) exclusive, fee -bearing, non -transferrablelicense to NLS’s patents and trademarks in connection with the commercialization, if any, of Nolazol in Latin America. The EF License Agreement is in effect until the later of either (i) ten years from the date of its execution, or until February 2029, or (ii) until the expiration of the last valid patent relating to